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A B S T R A C T 
Ultrasound has been developed for therapeutic 
use in addition to its diagnostic ability. The use of 
focused ultrasound energy can offer a non-invasive 
method for tissue ablation, and can therefore be 
used to treat various solid tumours. High-intensity 
focused ultrasound is being increasingly used 
in the treatment of both primary and metastatic 
tumours as these can be precisely located for 
ablation. It has been shown to be particularly useful 
in the treatment of uterine fibroids, and various 
solid tumours including those of the pancreas and 
liver. High-intensity focused ultrasound is a valid 
treatment option for liver tumours in patients with 
significant medical co-morbidity who are at high risk 
for surgery or who have relatively poor liver function 
that may preclude hepatectomy. It has also been used 
as a form of bridging therapy while patients awaiting 
cadaveric donor liver transplantation. In this article, 
we outline the principles of high-intensity focused 
ultrasound and its clinical applications, including 
the management protocol development in the 
treatment of hepatocellular carcinoma in Hong 
Clinical applications of high-intensity  
focused ultrasound
Introduction
High-intensity focused ultrasound (HIFU) was 
initially used in the 1940s to treat brain pathologies 
such as Parkinson’s disease.1-3 In the 1990s, it was 
introduced to ophthalmology to treat raised intra-
ocular pressure, traumatic capsular tears, glaucoma, 
retinal detachment, and vitreous haemorrhage.4-9 
This technique has a unique ability to target deep-
seated soft tissue tumours. Furthermore, as long as the 
lesions within solid organs can be clearly visualised on 
magnetic resonance imaging (MRI) or ultrasonography 
(USG)—that is, the presence of the acoustic window 
to allow the transmission of ultrasound energy—many 
lesions can be targeted such as those in the liver, 
kidney, pancreas and breast; and uterine fibroids, 
benign prostatic hypertrophy, and prostate cancer. In 
recent years, HIFU has been used to treat both benign 
and malignant lesions of various solid organs. This 
non-invasive modality allows treatment of tumours 
without surgery and offers a new treatment option for 
those patients who are not candidates for surgery, or 
who do not want surgery.
Methods
A search was performed on the following electronic 
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databases: MEDLINE (OVID), EMBASE, and 
PubMed. The search of these databases ranged 
from the date of their establishment until December 
2015. The search terms used were: high-intensity 
focused ultrasound, ultrasound, magnetic resonance 
imaging, liver tumour, hepatocellular carcinoma, 
pancreas, renal cell carcinoma, prostate cancer, 
breast cancer, fibroids, bone tumour, atrial 
fibrillation, glaucoma, Parkinson’s disease, essential 
tremor, and neuropathic pain. Only studies reported 
in English were included. Full papers were selected 
if they contained facts, data, or scientific evidence 
related to the treatment of HIFU. The reference 
lists of articles selected were screened for full-text 
review.
Mechanism of high-intensity 
focused ultrasound 
High-intensity focused ultrasound incorporates 
multiple ultrasound beams produced by 
piezoelectric or piezoceramic transducers directed 
into a three-dimensional focal point of typically 1 
to 5 mm in diameter and 10 to 50 mm in length.10 
Various mechanisms have been proposed for the 
subsequent tissue destruction with a synergistic 
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高強度聚焦超聲的臨床應用
石黃海、張丹圖、Caroline R Jenkins、Michael G Irwin
超聲具有診斷和治療雙重作用。聚焦的超聲能量為組織切除提供了一
種無創方法，故可用於治療不同腫瘤。高強度聚焦超聲（HIFU）能
準確地把腫瘤消融，所以在治療原發性和轉移性腫瘤方面越趨廣泛。
研究顯示HIFU對於消融子宮肌瘤，以及其他如肝臟和胰臟的腫瘤尤
其有效。對於患有其他嚴重疾病而不適合接受手術的病人，以及肝功
能較差而不能接受肝切除的病人，HIFU是一個有效的治療方案。另
外，對於正等待屍肝移植的病人，此技術也可作為橋接療法。我們利
用電子數據庫MEDLINE（OVID）、EMBASE和PubMed找出和以下
關鍵詞相關的文獻：高強度聚焦超聲、超聲、磁力共振、肝腫瘤、肝
細胞癌、胰腺、腎細胞癌、前列腺癌、乳腺癌、子宮肌瘤、骨腫瘤、
心房纖維性顫動、青光眼、帕金森氏病、特發性震顫和神經性疼痛，
並概括列出使用HIFU的原則及其臨床應用，包括香港治療肝癌模式
的發展。
effect from thermal and mechanical means. This 
technique induces heat generation due to absorption 
of the acoustic energy with the temperature rising 
rapidly to 60°C or higher, causing coagulation 
necrosis in a short period of time. Focusing is an 
important component as only a small volume (eg 1 
mm diameter and 9 mm length) is targeted by the 
ultrasound beam and hence HIFU induces minimal 
thermal damage to tissue located between the 
transducer and the focal point.11
 A mechanical effect is produced by acoustic 
pulses only at higher intensities. Various phenomena 
are observed, including cavitation, microstreaming, 
and radiation forces. Cavitation is defined as the 
creation or motion of a gas cavity in an acoustic 
field due to alternating compression and expansion 
of tissue as an ultrasound burst propagates through 
it.12 There are two forms of cavitation to consider: 
stable and inertial.11 If the tissue expansion or 
rarefaction pressure is of sufficient magnitude, gas 
can be extracted from the tissue, resulting in bubble 
formation. In stable cavitation, the bubble is exposed 
to a low-pressure acoustic field, resulting in stable 
oscillation of the size of the bubble. In inertial 
cavitation, exposure of the bubble to the acoustic 
filed results in violent oscillations of the bubble and 
rapid growth during the rarefaction phase, eventually 
leading to the violent collapse and destruction of 
the bubble. It will produce shock waves of very high 
pressure (20-30 000 bars) and a high temperature 
(2000-5000 K) in the microenvironment.13,14 Micro-
streaming is a phenomenon produced by stable 
cavitation in which rapid movement of fluid occurs 
near the bubble due to its oscillating motion. It can 
produce high shear forces that can cause transient 
damage to cell membranes and may play a role in 
ultrasound-enhanced drug or gene delivery when 
damage to the cell membrane is transient.13,15 
 Radiation forces are developed when a wave 
is either absorbed or reflected. If the reflecting or 
absorbing medium is tissue or other solid material, 
the force presses against the medium, producing a 
pressure termed ‘radiation pressure’. If the medium is 
liquid and can move under pressure, then streaming 
results.16 
 The intention of HIFU is to raise and maintain 
an isolated part of the volume above 60°C for 
more than 1 second or longer, in order to cause 
coagulative necrosis and immediate cell death.17,18 It 
aims to deliver the energy required to raise the tissue 
temperature to a cytotoxic level sufficiently fast that 
the tissue vasculature does not have a significant 
effect on the extent of cell killing.19,20 In a study of the 
application of HIFU in the liver, 2 hours of exposure 
resulted in a rim of glycogen-free cells of about 10 
cells wide. These cells were dead 48 hours later, 
and showed signs of coagulative necrosis typical of 
thermal injury.19 
Limitations of high-intensity 
focused ultrasound 
Of all the ablative modalities, HIFU has the advantage 
that it does not require the introduction of an 
applicator in order to achieve the ablative effect and 
is the only non-invasive option. This makes it a very 
attractive choice. It has several limitations, however. 
This technique is essentially USG and, therefore, any 
artefacts, such as acoustic shadowing, reverberation, 
and refraction also apply to it. Superficial lesions 
are treated most effectively by HIFU due to the 
limitations of ultrasound penetrance through many 
tissues, but the sound wave reflected carries very 
high energy, and can also produce burns in tissues 
that lie between the target and the transducer. Many 
collateral injuries have been reported due to scattered 
and reflected high-intensity ultrasound waves, such 
as skin burns, peripheral nerve damage, and bowel 
injury.21,22 Great care also needs to be taken in areas 
that are subject to respiratory movement, because of 
a lack of precision, or the presence of sonic shadowing 
due to overlying bony substances.21 In such 
situations it may be necessary for the anaesthetist 
to use controlled ventilation. The amount of energy 
absorbed by the tissue may vary, as fibrotic, fatty, and 
highly vascularised tissues attenuate sound energy 
differently. Excessive energy absorption may result in 
an unpredictable distribution of cell death.23 Careful 
planning is therefore required to ensure adequate 
tumour coverage, as coagulation, desiccation, and 
vapour formation are detrimental to ultrasound 
energy propagation, as well as precise localisation of 
the lesion.24   
The high-intensity focused 
ultrasound system
Both USG and MRI can be used to visualise, target, 
and monitor the status of tissue destruction.
  #  She et al #
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Ultrasonography
This is the most common method to target and 
monitor the status of HIFU destruction.25 The 
therapeutic and diagnostic transducers can be 
packaged into one instrument that allows real-time 
monitoring of the delivery of HIFU, the outcome 
of the lesion, and the outcome of the peripheral 
tissues. Although it is cost-effective, it has relatively 
low spatial resolution that limits its accuracy for 
targeting and it is also hard to visualise the details 
of the structures in close proximity to the bowel 
because of the gas-containing portions (air conducts 
sound very poorly). In our unit, we use an USG-
guided HIFU system.26
Magnetic resonance imaging
This offers excellent resolution and tumour detail. 
It locates the tumour boundary very clearly and is 
particularly useful in patients in whom tumours 
cannot be visualised with USG, for example, in obese 
patients.27 Magnetic resonance imaging possesses 
real-time thermal resolution with high spatial 
resolution, and provides temperature data within 
seconds of HIFU exposure. This allows detection of 
small temperature elevations before any irreversible 
tissue damage occurs.28 Nonetheless, MRI guidance 
is expensive, labour intensive, noisy, and bulky. 
Equipment such as that used for monitoring and 
anaesthesia needs to be non-ferrous and MRI-safe 
and treatment time is prolonged.
High-intensity focused ultrasound 
device
There are several devices available for the treatment 
of various diseases, including extracorporeal, 
transrectal, and interstitial devices.
Extracorporeal devices
Organs lying externally or those that are readily 
accessible—such as breasts, cutaneous tissue, limbs, 
abdomen, and brain—are usually treated with 
extracorporeal HIFU that is guided by either USG or 
MRI. As long as there is a suitable acoustic window 
on the skin that allows uninterrupted propagation 
of the HIFU energy beam to the target organs, one 
can consider the use of extracorporeal HIFU for 
treatment.
Ultrasonography-guided transcutaneous high-
intensity focused ultrasound 
We are currently using a HIFU machine produced 
by Haifu Technology Company (Chongqing, China) 
[Figs 1 to 3]. It has been used and shown to be effective 
in treatment of a variety of benign and malignant 
solid organ tumours, such as liver and pancreatic 
cancer, uterine fibroids, soft tissue tumours, breast 
cancer, and bladder cancer.29-31 This system consists 
of three selectable therapeutic transducers and a 
real-time imaging transducer. The transducers are 
mounted in a water reservoir with the beam axis 
directed upward, and the patient is positioned above 
the transducers in a prone or decubitus position.  The 
HIFU exposure level is adjusted until a hyperechoic 
region is seen on the USG image. 
Magnetic resonance imaging–guided high-
intensity focused ultrasound 
Two major clinical MRI-HIFU systems are available 
worldwide: InSightec (Tirat Carmel, Israel) and 
Philips Healthcare (Vantaa, Finland).32,33 Their HIFU 
FIG 1.  The usual setup of the high-intensity focused ultrasound (HIFU) system
(a) Control system; (b) HIFU machine and patient lying on the treatment table; and 
(c) anaesthetic machine
FIG 2.  Computer controls the degassed water in and out of the tank
(a) (b) (c)
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transducers are similar in terms of enabling both 
mechanical and electronic adjustment of HIFU focus 
and MR thermometric temperature monitoring, but 
their sonication strategies are different and hence 
they differ in energy efficiency.34 These machines are 
not available in Hong Kong. 
Transrectal devices
Transrectal devices were developed for the treatment 
of benign and malignant prostatic diseases. They aim 
to ablate the entire prostate. Both USG-guided probes 
and MRI-guided systems have been developed. The 
USG probes are inserted per rectum and incorporate 
both imaging and therapeutic transducers in one 
unit,35-41 such as Ablatherm (Edap Technomed, 
France) and the Sonablate (Focus Surgery Inc, US), 
whereas a prostate-dedicated MRI-HIFU system 
makes use of either the transrectal (ExAblate OR; 
InSightec) or transurethral (Philips Healthcare) 
approach.42,43 
Interstitial devices
Ultrasonographic transducers with different shapes 
and sizes were developed in order to place the focused 
applicators as close as possible to the target area. 
Several shapes are available, including cylindrical, 
semi-cylindrical, cylindrical with focusing by wave 
reflection, plane and cylindrical array. Various 
applicators have been developed to facilitate access 
and guidance of the device, such as the flexible 
applicator in an endoscopically placed HIFU 
device for the treatment of cholangiocarcinoma44 
or oesophageal tumours45; or rigid applicators for 
a linear approach. Probes for percutaneous and 
laparoscopic treatment are also being developed 
and it is likely that the therapeutic indications will 
increase.
Current clinical applications
High-intensity focused ultrasound has been used to 
treat various benign and malignant solid tumours. It 
is also used in conditions such as ablation for atrial 
fibrillation,46 glaucoma,47 and benign obstetric and 
gynaecological procedures such as fibroids.32
Liver tumours
In general, liver resection is still the mainstay of 
treatment of hepatocellular carcinoma (HCC), 
provided the patient is surgically fit, has fair liver 
function with good liver remnant and resectable 
tumour. Liver transplantation is planned for patients 
whose tumour is within the transplant criteria, and a 
living or deceased donor is available. 
 Ablative therapy, such as radiofrequency 
ablation (RFA), is considered for patients with a 
relatively small tumour, preserved liver function, 
and favourable location, that is, away from pleural 
or gastrointestinal tract. For those patients whose 
FIG 3.  The lesion (arrow) is identified and fired by high-intensity focused ultrasound
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tumours are relatively small, located at the dome of 
the liver, with clinical evidence of ascites or pleural 
effusion, HIFU would be an alternative as long as 
the lesion can be visualised and located by USG. 
For those patients with multifocal tumours that are 
not amenable to surgical resection or ablation, and 
who have reasonable liver function without evidence 
of ascites, transarterial chemoembolisation is the 
treatment of choice. Sorafenib is an effective target 
therapy for patients undergoing palliative care, but 
has significant side-effects.
 High-intensity focused ultrasound is now 
one of the treatment modalities in our centre for 
HCC and has been used as bridging therapy for 
patients who are awaiting cadaveric donor liver 
transplantation. This technique can be utilised for 
patients who are not suitable for percutaneous RFA 
but have a satisfactory general condition as assessed 
by an anaesthesiologist. They should have intact skin 
over the ablative region.
High-intensity focused ultrasound treatment 
procedure
Before treatment, the patient undergoes USG screen-
ing to ensure that the targeted lesions are visible on 
the USG localisation system. An anaesthesiologist 
will assess the patient’s co-morbidities and suitability 
for general anaesthesia as many patients may be 
unfit for open surgery. Standard fasting and drug 
administration guidelines apply. Before treatment 
starts, the patient’s skin is cleansed with degassed 
water and a negative-pressure aspirator is used to 
degas the skin and reduce the dampening effect of 
ultrasonic waves. 
 We use the JC HIFU system (Chongqing Haifu 
Technology, Chongqing, China); HIFU ablation 
is performed under general anaesthesia by a team 
of surgeons and radiologists. Total intravenous 
anaesthesia is favoured in our centre because of 
its titratability, avoidance of nitrous oxide, and no 
need for scavenging waste anaesthetic gases that 
may be hazardous to the health of attendant staff.48 
A dose of antibiotic (Augmentin 1.2 g; Beecham 
Pharmaceuticals, Brentford, UK) is given just before 
the procedure begins. Artificial pleural effusion of 
500 mL of normal saline is introduced if the liver 
tumour is located at the dome, in order to facilitate 
better ultrasound access to this region and protect 
the lung. In addition, intermittent cessation of 
respiratory movement by the anaesthesiologist 
facilitates better localisation of the lesions during 
energy transfer. For right-sided lesions, the patient 
is placed in the right lateral position after tracheal 
intubation. For left-sided lesions, the patient is placed 
in the prone position. The JC HIFU system consists 
of a treatment unit that delivers focused ultrasound 
energy with a focal length of 12 cm deep. The body 
is immersed in a degassed water circulation unit that 
provides a medium for ultrasound transmission. 
Grey-scale changes at the ablation site are observed 
during the procedure, indicating the temperature 
change inside the targeted lesion. Oral antibiotics 
are given for 5 days after treatment.49
 When ablating a large tumour, the ultrasound 
energy is focused on the deep margin of the lesion 
first so as to avoid prohibition of effective penetration 
of energy by the cavitation effect and the presence 
of coagulation necrosis. Meticulous planning of 
the focus point before the procedure, in which 
the ablation sequence is from the deepest layer to 
the most superficial layer, is required for maximal 
destruction of the targeted lesion. Intermittent 
cessations of the procedure allow recovery of the 
cavitation effect shown under USG monitoring, 
giving additional allowance for ablation of the 
residual lesion in the periphery.50
Treatment results
Although a minimally invasive approach can 
be employed in patients with HCC and liver 
cirrhosis, hepatectomy is contra-indicated in 
patients with decompensated cirrhosis.51 Our pilot 
studies suggested that HIFU is relatively safe and 
effective.52,53 Patients who have poor liver function 
can still be offered HIFU.54 Its effectiveness in 
treating small HCC of size <3 cm was proven to be 
comparable with percutaneous RFA.55 Furthermore, 
its application in recurrent HCC allows patients to 
undergo ablation, especially when the abdomen is 
hostile due to previous surgery, or there is inadequate 
liver remnant due to previous major hepatectomy.56 
In the treatment of HCC in non-surgical candidates, 
1- and 3-year overall survival rates of 87.7% and 
62.4%, respectively were achieved in 49 patients with 
a median tumour size of 2.2 cm.49 In addition, our 
prospective study suggested that the response rate 
for those patients with HCC who underwent HIFU 
as the bridging treatment while awaiting cadaveric 
liver transplantation was higher than in those who 
underwent transarterial chemoembolisation.52 It is 
particularly useful in patients who also have poor 
liver function with clinical ascites, as ascites itself is 
a good acoustic media for HIFU.57 
 High-intensity focused ultrasound does carry 
certain risks in the treatment for HCC. Minor 
complications such as skin and subcutaneous tissue 
injury occur in most patients.54 At our centre, there 
has been a case of post-HIFU bile duct stricture 
requiring endoscopic retrograde cholangiography. 
Pancreatic cancer
Inoperable locally advanced pancreatic cancer 
remains difficult to treat. Local ablative therapy with 
HIFU has been used in patients with unresectable 
pancreatic cancer and proven to be safe in both 
clinical trials and retrospective studies,31,58-60 with 
#  High-intensity focused ultrasound  # 
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no damage to the exocrine or endocrine function.61-63 
It has been used as a form of palliative treatment in 
some pilot studies with a median survival ranging 
from 10 to 12.6 months, either alone or combined 
with chemotherapy.62-65 Pain relief was also found 
to be effective.31,58,59,63,65,66 Unfortunately, treatment 
after HIFU usually lacked histomorphological 
examination. The survival benefit needs to be tested 
in further studies, and preferably confirmed by 
randomised controlled trials. 
Urological applications
Prostate cancer
Transrectal HIFU is advocated as a form of minimally 
invasive treatment for localised prostate cancer. 
It is suggested primarily for patients with low- to 
intermediate-risk prostate cancer, according to 
D’Amico Risk stratification.67-72 It has also been used 
to treat locally recurrent prostate cancer. Patients 
with unifocal and multifocal prostate cancer were 
subjected to HIFU and had no evidence of disease on 
MRI at 12 months.73 Good functional outcome was 
achieved after the treatment, such as continence and 
good erectile function. Nonetheless, complications 
such as acute retention of urine or more severe rectal 
wall injury can occur. More sophisticated MRI-
guided HIFU will allow more precise localisation 
of such lesions.74 To date, most studies have been in 
the form of retrospective studies or case series only 
with no randomised controlled trial of HIFU for the 
treatment of prostate cancer.
Renal tumours
International consensus panels recommend ablative 
techniques in patients who are unfit for surgery, 
who are not considered candidates for or elect 
against active surveillance, and who have a small 
renal mass.75,76 European Association of Urology 
guidelines recommend the use of an ablative method 
only in tumours of less than 4 cm.76 In fact, HIFU 
has been investigated in the treatment of both 
primary and metastatic renal tumours.77-79 Results 
suggest that there were discrete zones of ablation 
in 67% of patients in the final histology and HIFU 
achieved stable lesions in two thirds of patients 
with minimal morbidity; 90% of patients had good 
pain control immediately after HIFU.79 There were 
several limitations, however, such as the degree of 
subcutaneous and perinephric fat and the position 
of the tumour in relation to the ribs.80 Higher 
acoustic output is needed to compensate for the 
energy loss due to the thickness of the perinephric 
fat that might in turn increase the risk of prefocal 
and surrounding tissue damage.81 Currently, there 
is no controlled study to suggest the superiority of 
HIFU over various ablative techniques, such as RFA 
or cryoablation.
Brain diseases 
High-intensity focused ultrasound was first used in 
the 1950s to treat Parkinson’s disease.82-84 It required 
access through the skull to the brain and, therefore, 
craniotomy was necessary. It subsequently became 
unpopular due to the concurrent development of 
the drug levodopa. With the advancement of MRI 
guidance, there has been a resurgence of interest 
as a non-invasive treatment for essential tremor, 
neuropathic pain, and Parkinson’s disease. It is 
safe, without major risk of infection or bleeding, 
but may result in transient oedema. In Parkinson’s 
disease, as the disease progresses, patients will 
eventually require levodopa that is associated with 
tolerance and, eventually, development of levodopa-
resistant symptoms with movement fluctuations and 
dyskinesias. At this time surgical intervention may 
be considered. High-intensity focused ultrasound 
can allow ablation of the fibres that join the thalamus 
with the globus pallidus. Results of a pilot study 
suggested that there was improvement in terms of the 
functional score as rated by the Unified Parkinson’s 
Disease Rating Scale.85
 Essential tremor is a common neurological 
condition usually managed conservatively, or with 
propranolol and primidone. For those treatment-
resistant patients, surgical intervention may be 
considered. Usually RFA, stereotactic radiosurgery, 
gamma knife thalamotomy, or deep brain stimulation 
are used to either cause tissue destruction or to block 
abnormal nerve signals. High-intensity focused 
ultrasound has been used in a clinical trial context 
with promising results and marked reduction (>80%) 
of tremor.86,87
 Neuropathic pain is a complex condition 
often associated with damage to or dysfunction of 
the nerve fibres that then send incorrect signals to 
the pain centres with minimal stimulation. High-
intensity focused ultrasound can be directed to the 
part of the central lateral thalamic nucleus of those 
patients suffering from chronic therapy-resistant 
neuropathic pain. Significant pain relief has been 
observed with long-term follow-up in a pilot study.88
Breast tumour 
High-intensity focused ultrasound is an ideal breast-
conserving therapy because it does not significantly 
change the patients’ breast shape and does not cause 
bleeding or scarring. It does not require general 
anaesthesia, and hence has a reduced recovery 
time. Both USG- and MRI-guided HIFU ablations 
have been used. The aim is to achieve complete 
tumour necrosis but results have been inconsistent 
with some showing complete necrosis,89 and others 
residual tumour of less than 10% and residual tumour 
between 10% and 90%.90-94 A negative margin is the 
most important basis and factor for local control 
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of the breast cancer.95,96 Nonetheless, it is difficult 
to ensure a negative margin after HIFU therapy 
with the aid of imaging alone, hence adjuvant 
radiotherapy has been suggested. Currently, there is 
limited prospective study or randomised trial in this 
area. Most work has been pilot studies or feasibility 
studies only.
 Complications include pain, skin burns, 
oedema, pectoralis major muscle injury,97 and rib 
pain.98 These are relatively minor compared with 
those following traditional breast surgery with its 
attendant potential complications of wound pain, 
infection, bleeding, and impaired wound healing. 
Fibroids
Uterine fibroid is a common benign gynaecological 
condition in women of childbearing age. Patients 
usually suffer symptoms such as heavy, painful, 
and prolonged menstrual bleeding, mass effect 
with urinary urgency, and constipation.99 
Conservative medical therapy with non-steroidal 
anti-inflammatory drugs, contraceptive steroids, 
and gonadotropin-releasing hormone agonists are 
the first-line treatment. Ablative treatment as well 
as surgery will be necessary for those in whom 
conservative management fails or in those with 
progressive symptoms. Treatment is by means of 
myomectomy or hysterectomy. In cases where the 
patient does not want surgery, or where the patient 
is planning a future pregnancy, HIFU is a good 
option.100,101 Extracorporeal HIFU enables ablation 
of various sizes and shape of fibroid. Symptoms are 
reduced by more than 50% in terms of pain,102-104 
bulk-related and menstrual symptoms, comparable 
with the results of conventional surgery.105 After 
HIFU, the ablated fibroid volume is decreased, and 
is related to the non-perfused volume of the tumour 
immediately after treatment.44,106,107 Nonetheless, 
HIFU cannot propagate through air-filled viscera 
such as bowel. There is a potential risk of bowel 
perforation if it lies close to the fibroids.108 Most of 
the articles were from China, as HIFU has been used 
in China for treatment of fibroids. In our hospital, 
the following criteria are used for patient selection: 
(1) premenopausal women with no plans for further 
childbearing; (2) severe fibroid symptoms (as defined 
by a transformed symptom severity score of >41 on 
the Uterine Fibroid Symptom and Quality of Life 
questionnaire); (3) a clinical uterine size of less than 
20 weeks’ gestation, a dominant fibroid of less than 
10 cm in diameter without areas of necrosis as judged 
by contrast-enhanced MRI, a non-pedunculated 
fibroid, and a fibroid not suspicious of malignancy; 
(4) no evidence of known or suspected extensive 
pelvic adhesions such as history of acute pelvic 
inflammatory disease, severe pelvic endometriosis, 
or lower abdominal surgery; and (5) an abdominal 
wall thickness of less than 5 cm.109
Bone tumour
Bone metastases
In palliative treatment of bone tumours, therapeutic 
goals include pain palliation, tumour reduction, 
prevention of impending pathological fractures, and/
or tumour decompression. Opioid analgesics and 
radiation therapy are widely used for pain control in 
patients suffering from bone metastases but this does 
not always provide desired relief in many patients 
and is associated with undesirable side-effects.110-115 
Research reveals that MRI-guided HIFU is safe 
and effective in the treatment of painful bone 
tumours.116-118 Periosteal denervation and tumour 
debulking may play a significant role in symptom 
relief.74,116,117 Response to HIFU is rapid and good 
pain control has been seen within days of treatment. 
This greatly improves the quality of life for many 
patients with disseminated cancer.119 There is also 
evidence of a reduction in lesion viability after HIFU 
and a remineralisation of spongious bone.120
 Tumour ablation in curative treatment aims for 
complete coagulation necrosis of the primary lesion. 
Primary bone malignancy such as osteosarcoma 
has been treated with HIFU. A combination of 
chemotherapy with HIFU seems to be as effective 
as limb-sparing surgery and chemotherapy for 
malignant bone tumours.121 This is potentially useful 
for patients who are not fit for surgery. Treatment 
complications include skin burns, procedure-related 
pain, and post-treatment fractures.121,122 Most of the 
studies were clinical trials. More studies should focus 
on the treatment outcome in terms of the function, 
quality of life, and survival.
Glaucoma
The specific advantage of HIFU is that the energy 
can be focused through non-optically transparent 
media without uncontrolled energy absorption, thus 
reducing the effects on adjacent tissues. It allows a 
defined and adjustable tissue volume to be heated 
and treated at any depth or location within the eye. 
Intra-ocular pressure is decreased both by reducing 
aqueous humour production (aqueous inflow) and 
by facilitating the evacuation of aqueous humour 
from the eye (aqueous outflow).123 Prospective case 
series suggest there is a significant reduction in 
intra-ocular pressure without significant peri- or 
post-treatment side-effects.124
Atrial fibrillation
High-intensity focused ultrasound has been used 
to treat atrial fibrillation in cardiac surgery. This is 
designed to deliver pulmonary vein and posterior 
left atrial wall isolation on the beating heart using 
an encircling ‘cinch’ and create left atrial lines using 
a handheld wand device. It then ablates areas around 
the ganglionic plexi where dense collections of 
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complex fractionated atrial electrograms are found. 
It has been proven to be safe and effective.125 Patients 
can be reverted to sinus rhythm and the results 
are more pronounced in patients with paroxysmal 
atrial fibrillation.46,126 Selected use of this technique 
has been suggested.127 If symptoms persist, other 
modalities should be considered.125
Conclusions
High-intensity focused ultrasound has many 
applications in both benign and malignant diseases. 
It offers an alternative to those patients for whom 
surgery is contra-indicated or inappropriate. The 
results of HIFU in the management of HCC patients 
in our centre are particularly promising. Further 
studies of the application of HIFU in various organs 
should be conducted for both clinical trials as well as 
comparative studies with other ablative modalities in 
the form of randomised controlled trials.
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